Resminostat

DB12392InvestigationalSmall molecule

Resminostat has been used in trials studying the treatment of Sezary Syndrome, Mycosis fungoides, Hodgkin's Lymphoma, Hepatocellular Carcinoma, and Lymphoma, T-Cell, Cutaneous, among others.

Formula / weight: C₁₆H₁₉N₃O₄S · 349.41 g/mol (avg)
Code names: 4SC-201 · BYK-408740 · RAS-2410

Resolves to

Compound

UNII1578EUB98LCAS864814-88-0ChEMBLCHEMBL4296717PubChem11609955

Clinical / RWD

ATCL01XH07

Structure

InChIKeyFECGNJPYVFEKOD-VMPITWQZSA-NSMILESCN(C)CC1=CC=C(C=C1)S(=O)(=O)N1C=CC(\C=C\C(=O)NO)=C1

Targets

Q13547HDAC1

What you can answer from here — as of August 30, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 9 drug categories

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Resminostat, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account